Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106
INBRX106-01-201
Phase 3 small_molecule active
Quick answer
Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106 for Head and Neck Squamous Cell Carcinoma is a Phase 3 program (small_molecule) at Inhibrx Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Inhibrx Biosciences
- Indication
- Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active